Opportunity Knocks: In-Licensed Drug Products Can Signal Outsourcing Opportunity

List Price: US $750
Delivery format: Electronic PDF delivery within one business day upon payment.

*This report is included at no extra cost for STRATEGIC ADVANTAGE clients, and is accessible in the Trend Reports section here. Learn more about PharmSource STRATEGIC ADVANTAGE outsourcing intelligence portal.


Of the more than 230 New Molecular Entities (NMEs) approved between 2003-2013, over one-third were in-licensed by the sponsor receiving the approval. A significant difference in manufacturing status emerged between products originally discovered in-house and those in-licensed from external partners. During this period 66% of in-licensed NMEs were either outsourced completely or partially, compared to 44% for internally discovered candidates.

According to the latest PharmSource Trend Report, Opportunity Knocks: In-Licensed Drug Products Can Signal Outsourcing Opportunity, in-licensing of NMEs is an important positive signal to the CDMO sector that a candidate is likely to be successful and its manufacture is likely to be outsourced.

Who should buy this report?

The 7-page report provides important insight that you won’t find in any other source. This report is required reading for:

  • CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
  • Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.

Published November 2014